LONDON (Reuters) - GlaxoSmithKline has completed its $3 billion acquisition of long-time biotech partner Human Genome Sciences, after buying all the outstanding shares for $14.25 each in cash, Britain's biggest drugmaker said on Friday. The deal secures it full rights to recently launched lupus drug Benlysta and other experimental medicines. (Reporting by Ben Hirschler) via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment